References
- Barecki ME, Casciano CN, Johnson WW, Clement RP. 2001. In vitro characterization of the inhibition of loratadine, desloratadine and 3-0H-desloratadine for five human cytochrome P-450 enzymes. Drug metabolism and disposition 29:1173–1175.
- Barret A. 1998. New teeth for old patents. Business Week 30 November:92–94.
- Bu HZ, Pool WF, Wu EY, Raber SR, Amantea MR, Shetty By. 2004. Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug metabolism and disposition 32:689–698.
- Chowdhury SK, Alvarez N, Su AD, Ramanathan R, Feng W, Aslanian R, Alton KB, Patrick JE. 2001. Identification of a novel metabolic pathway in the metabolism of desloratadine in rats. Paper presented at the 49th American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics, Chicago, IL, USA.
- Ghosal A, Gupta S, Chowdhury S, Yuan Y, Lu X, Horne D, Su A, Alvarez N, Ramanathan R, Hanna I, Alton K, Patrick J, Zbaida S. 2003. Identification of human cytochrome P450 enzymes that metabolize loratadine (LOR). Drug Metabolism Reviews 38:111.
- Hilbert J, Radwanski E, Weglein R, Luc V, Perentesis G, Symchowicz S, Zampaglione N. 1987. Pharmacokinetics and dose proportionality of loratadine. Journal of Clinical Pharmacology 27:694–698.
- Johnson R, Christensen J, Lin CC. 1994. Sensitive gas—liquid chromatographic method for the determination of loratadine and its major active metabolite, descarboethoxyloratadine, in human plasma using nitrogen-phosphorus detector. Journal of Chromatography B Biomedical Applications 657:125–131.
- Kalgutkar AS, Taylor TJ, Venkatakrishnan K, Isin EM. 2003. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metabolism and Disposition 31:243–249.
- Katchen B, Cramer J, Chung M, Gural R, Hilbert J, Luc V, Mortizen V, D'souza R, Symchowicz S, Zamaglione N. 1985. Disposition of "C-SCH 29851 in human. Annals of Allergy 55:393.
- Kay GG, Harris AG. 1999. Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Clinical Experiment in Allergy 29\(Suppl. 3):147–150.
- Lin SN, Walsh SL, Moody DE, Foltz RL. 2003. Detection and time course of cocaine N-oxide and other cocaine metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Annals in Chemistry 75:4335–4340.
- Piwinski J, Wong JK, Chan TM, Green MJ, Ganguly AK. 1990. Hydroxylated metabolites of loratadine: An example of conformational diastereomers due to atropisomerism. Journal of Organic Chemistry 55:3341–3350.
- Radwanski E, Hilbert J, Symchowicz S, Zampaglione N. 1987. Loratadine, multiple-dose pharmacokinetics. Journal of Clinical Pharmacokinetics 27:530–533.
- Ramanathan R, Su AD, Alvarez N, Blumenkrantz N, Chowdhury SK, Alton K, Patrick J. 2000. Liquid chromatography/mass spectrometry methods for distinguishing N-oxides from hydroxylated metabolites. Annals of Chemistry 72:1352–1359.
- Sakamoto K, Nakamura Y. 1993. Urinary metabolites of pinacidil II. species difference in the metabolism of pinacidil. Xenobiotica 23:649–656.
- Yumibe N, Huie K, Chen K, Clement RP, Cayen MN. 1995. Identification of human liver cytochrome P-450s involved in the microsomal metabolism of the antihistamine drug loratadine. International Archives in Allergy Immunology 107:420–429.
- Yumibe N, Huie K, Chen KJ, Snow M, Clement RP, Cayen MN. 1996. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochemical Pharmacology 51:165–172.